Search Results - "Phillips, Gordon L. II"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
  2. 2

    Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia by Reid, Robin, Bennett, John M., Becker, Michael, Chen, Yuhchyau, Milner, Laurie, Phillips II, Gordon L., Liesveld, Jane

    Published in American journal of hematology (01-07-2012)
    “…Persistent thrombocytopenia after stem cell transplantation can lead to increased morbidity and mortality [1,2]. The underlying causes are often multifactorial…”
    Get full text
    Journal Article
  3. 3

    How Do We Define Cure of Diabetes? by Buse, John B, Caprio, Sonia, Cefalu, William T, Ceriello, Antonio, Del Prato, Stefano, Inzucchi, Silvio E, McLaughlin, Sue, Phillips, Gordon L. II, Robertson, R. Paul, Rubino, Francesco, Kahn, Richard, Kirkman, M. Sue

    Published in Diabetes care (01-11-2009)
    “…The group considered a wide variety of questions, including whether it is ever accurate to say that a chronic illness is cured; what the definitions of…”
    Get full text
    Journal Article
  4. 4

    Proteasome Inhibition in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Cell Lines by Liesveld, Jane L., Rosell, Karen E., Bechelli, Jeremy, Lu, Chaohui, Messina, Patti, Mulford, Deborah, Ifthikharuddin, J. J., Jordan, Craig T., Phillips II, Gordon L.

    Published in Cancer investigation (01-08-2011)
    “…In this work, effects of bortezomib on apoptosis, clonal progenitor growth, cytokine production, and NF-κB expression in patients with MDS with cytopenias…”
    Get full text
    Journal Article
  5. 5

    New cancer therapies. Are haematopoietic cell transplants a dead duck? by Gale, Robert Peter, Phillips, Gordon L., Lazarus, Hillard M.

    Published in Bone marrow transplantation (Basingstoke) (01-05-2021)
    “…Recent therapy advances for haematological cancers including new drugs and targeted and immune therapies raise the question whether there is a future for…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA by Hashmi, Shahrukh, Mooney, Chris, Phillips, Gordon L. II, Liesveld, Jane L., Ifthikharuddin, Jainulabdeen J

    Published in Blood (19-11-2010)
    “…Abstract 2557 Stem cell transplantation, better supportive care, and the introduction of “novel agents”, particularly proteosome inhibitors and IMIDS, have…”
    Get full text
    Journal Article
  9. 9

    Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective by Reid, Robin M., Baran, Andrea, Friedberg, Jonathan W., Phillips, Gordon L., Liesveld, Jane L., Becker, Michael W., Wedow, Lucy, Barr, Paul M., Milner, Laurie A.

    Published in Cancer medicine (Malden, MA) (01-11-2016)
    “…High‐dose BEAM chemotherapy (BCNU, etoposide, Ara‐C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as…”
    Get full text
    Journal Article
  10. 10

    Adenovirus Infections in Hematopoietic Stem Cell Transplant Recipients by Howard, Dianna S., Phillips, Gordon L., Reece, Donna E., Munn, Rita K., Henslee-Downey, Jean, Pittard, Melissa, Barker, Matthew, Pomeroy, Claire

    Published in Clinical infectious diseases (01-12-1999)
    “…We report a 12% incidence of adenovirus infections among 532 recipients of hematopoietic stem cell transplant (HSCT) from January 1986 through March 1997. The…”
    Get full text
    Journal Article
  11. 11

    A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia by Howard, Dianna S, Liesveld, Jane, Phillips, Gordon L, Hayslip, John, Weiss, Heidi, Jordan, Craig T, Guzman, Monica L

    Published in Leukemia research (01-11-2013)
    “…Abstract We report the results of a phase I study with four dose levels of bortezomib in combination with idarubicin. Eligible patients were newly diagnosed…”
    Get full text
    Journal Article